Peter O’Gorman

3.3k citations

72 papers · 1.8k indexed · h-index 23

Impact in

Hematology top 1%
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
Oncology top 5%
- Peptidase Inhibition and Analysis
- Bone health and treatments

Papers in ⓘ

Hematology 45
- Multiple Myeloma Research and Treatments 37
Oncology 22
- Peptidase Inhibition and Analysis 13
- Cancer Treatment and Pharmacology 4

Co-authors: Paul Dowling (26 shared papers)Martin Clynes (11 shared papers)Despina Bazou (21 shared papers)Tadhg G. Gleeson (3 shared papers)Conor Shortt (2 shared papers)Abdul Hameed (4 shared papers)Stephen Eustace (2 shared papers)Jennifer J. Brady (3 shared papers)
Journals: Blood (13 papers)Cancers (5 papers)British Journal of Haematology (4 papers)Drug and Alcohol Dependence (3 papers)Clinica Chimica Acta (3 papers)
Partner nations: Ireland United States United Kingdom

In The Last Decade

Peter O’Gorman

66 papers receiving 1.7k citations

Peers

Countries citing papers authored by Peter O’Gorman

Since Specialization

Citations

This map shows the geographic impact of Peter O’Gorman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter O’Gorman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter O’Gorman more than expected).

Fields of papers citing papers by Peter O’Gorman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter O’Gorman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter O’Gorman. The network helps show where Peter O’Gorman may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter O’Gorman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter O’Gorman Line = papers co-authored together Peter O’Gorman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 72 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution Blood ·Suparno Chakrabarti, Stephen Mackinnon, Raj Chopra, Panagiotis Kottaridis, Karl S. Peggs, Peter O’Gorman, Ronjon Chakraverty, Timothy Marshall, Husam Osman, Premini Mahendra, Charles Craddock, Herman Waldmann, G Hale, Chris Fegan, Kwee Yong, Anthony H. Goldstone, David C. Linch, Donald Milligan	2002	300
2	Whole-Body MRI Versus PET in Assessment of Multiple Myeloma Disease Activity American Journal of Roentgenology ·Conor Shortt, Tadhg G. Gleeson, Karen Breen, John C. McHugh, Martin J. O’Connell, Peter O’Gorman, Stephen Eustace	2009	130
3	Bone Disease in Multiple Myeloma: Pathophysiology and Management SHILAP Revista de lepidopterología ·Abdul Hameed, Jennifer J. Brady, Paul Dowling, Martin Clynes, Peter O’Gorman	2014	127
4	Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI) Skeletal Radiology ·Tadhg G. Gleeson, John M. Moriarty, Conor Shortt, James P. Gleeson, Patricia Fitzpatrick, Brenda Byrne, Johnny McHugh, Martin O’Connell, Peter O’Gorman, Steven J. Eustace	2008	118
5	Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis Cancers ·Matthew Ho, Emma Kavanagh, Luke Dunne, Paul Dowling, Li Zhang, Sinéad Lindsay, Despina Bazou, Chia Yin Goh, Cathal Hanley, Giada Bianchi, Kenneth C. Anderson, Peter O’Gorman, Amanda McCann	2019	89
6	Protein and chemotherapy profiling of extracellular vesicles harvested from therapeutic induced senescent triple negative breast cancer cells Oncogenesis ·Emma Kavanagh, Sinéad Lindsay, Melinda Halász, Luke Gubbins, Karolina Weiner‐Gorzel, Matthew Ho, Alo McGoldrick, E.Dale Collins, Michael Henry, Alfonso Blanco, Peter O’Gorman, Patricia Fitzpatrick, Michaela J. Higgins, Paul Dowling, Amanda McCann	2017	80
7	Multiple Myeloma: A Review of Imaging Features and Radiological Techniques PubMed ·Ciaran F. Healy, John G. Murray, Stephen Eustace, John E. Madewell, Peter O’Gorman, P.J. O’Sullivan	2011	65
8	The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias Cancer Chemotherapy and Pharmacology ·Robert O’Connor, Melissa Ooi, Justine Meiller, Jana Jakubı́ková, Steffen Klippel, Jake Delmore, Paul G. Richardson, Kenneth C. Anderson, Martin Clynes, Constantine S. Mitsiades, Peter O’Gorman	2013	56
9	COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies British Journal of Haematology ·Eleonora Calabretta, José M. Moraleda, Massimo Iacobelli, Rubén Jara, Israël Vlodavsky, Peter O’Gorman, Antonio Pagliuca, Clifton C. Mo, Rebecca M. Baron, Alessio Aghemo, Robert J. Soiffer, Jawed Fareed, Carmelo Carlo‐Stella, Paul G. Richardson	2021	56
10	Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib Clinical Cancer Research ·Melissa Ooi, Patrick Hayden, Vassiliki Kotoula, Douglas W. McMillin, Elpida Charalambous, Emily Daskalaki, Noopur Raje, Nikhil C. Munshi, Dharminder Chauhan, Teru Hideshima, Leutz Buon, Martin Clynes, Peter O’Gorman, Paul G. Richardson, Constantine S. Mitsiades, Kenneth C. Anderson, Nicholas Mitsiades	2009	53
11	A multi‐centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia British Journal of Haematology ·Su Wai Maung, Martin J. Leahy, Hilary M O'Leary, Irfan Khan, Mary R. Cahill, Oonagh Gilligan, Philip Murphy, Suzanne McPherson, F. Jackson, Mary Ryan, Bryan T. Hennessy, Johnny McHugh, Matthew Goodyer, Larry Bacon, Peter O’Gorman, Aisling Nee, Michael O’Dwyer, Helen Enright, Jean Saunders, Denis O’Keeffe	2013	42
12	Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers Cancers ·Katie Dunphy, Paul Dowling, Despina Bazou, Peter O’Gorman	2021	42
13	Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen Cancers ·Juho J. Miettinen, Romika Kumari, Gunnhildur Ásta Traustadóttir, Maiju-Emilia Huppunen, Philipp Sergeev, Muntasir Mamun Majumder, Alexander Schepsky, Þórarinn Guðjónsson, Juha Lievonen, Despina Bazou, Paul Dowling, Peter O’Gorman, Ana Slipicevic, Pekka Anttila, Raija Silvennoinen, Nina N. Nupponen, Fredrik Lehmann, Caroline A. Heckman	2021	39
14	Blood vitamin status (B1, B2, B6, folic acid and B12) in patients with alcoholic liver disease. PubMed ·Majumdar Sk, Shaw Gk, Peter O’Gorman, Aps Ej, Offerman El, Thomson Ad	1982	39
15	High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury Annals of Clinical Biochemistry International Journal of Laboratory Medicine ·Melissa Jones, Peter O’Gorman, Catherine M. Kelly, Niall Mahon, Maria Fitzgibbon	2016	38
16	Two cases of aplastic anaemia associated with tumours of the thymus Journal of Clinical Pathology ·R. D. Barnes, Peter O’Gorman	1962	34
17	Polyclonal Immunoglobulin G N-Glycosylation in the Pathogenesis of Plasma Cell Disorders Journal of Proteome Research ·Stefan Mittermayr, Giao Lê, Colin Clarke, Silvia Millán‐Martín, Annemarie Larkin, Peter O’Gorman, Jonathan Bones	2016	32
18	Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease BMC Genomics ·Paul Dowling, Catriona A. Hayes, Kay Reen Ting, Abdul Hameed, Justine Meiller, Constantine S. Mitsiades, Kenneth C. Anderson, Martin Clynes, Colin Clarke, Paul G. Richardson, Peter O’Gorman	2014	30
19	Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder British Journal of Haematology ·Eleni Tholouli, C. R. M. Hay, Peter O’Gorman, Michael Makris	2004	30
20	Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’ Leukemia & lymphoma ·Matthew Ho, Amanda McCann, Giada Bianchi, Li Zhang, Paul Dowling, Despina Bazou, Peter O’Gorman, Kenneth C. Anderson	2017	29

About Peter O’Gorman

Peter O’Gorman is a scholar working on Hematology, Oncology, Pathology and Forensic Medicine, Spectroscopy and Genetics, having authored 72 papers that have together received 1.8k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (37 papers), Protein Degradation and Inhibitors (14 papers), Peptidase Inhibition and Analysis (13 papers), Advanced Proteomics Techniques and Applications (7 papers), Liver Disease Diagnosis and Treatment (5 papers), Cancer Treatment and Pharmacology (4 papers), Drug-Induced Hepatotoxicity and Protection (4 papers) and Alcohol Consumption and Health Effects (4 papers). The work is most often cited by research in Hematology (889 citations), Oncology (571 citations), Genetics (131 citations), Immunology (225 citations) and Transplantation (27 citations). Peter O’Gorman has collaborated with scholars based in Ireland, United States and United Kingdom. Frequent co-authors include Paul Dowling, Martin Clynes, Despina Bazou, Tadhg G. Gleeson, Conor Shortt, Abdul Hameed, Stephen Eustace, Jennifer J. Brady, Kenneth C. Anderson and Shanta Patel. Their work appears in journals such as Blood, Cancers, British Journal of Haematology, Drug and Alcohol Dependence and Clinica Chimica Acta.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact